



I-MAB
BIOPHARMA

I-Mab to Participate at the H.C. Wainwright 26th Annual Global Investment Conference

August 26, 2024

ROCKVILLE, Md., Aug. 26, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB), a US-based, global, clinical-stage biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that management will present at the H.C. Wainwright 26th Annual Global Investment Conference on September 10, 2024.

H.C. Wainwright 26th Annual Global Investment Conference

Presentation Time	Tuesday, September 10 at 5:00 PM ET
Presenters	Sean Fu, PhD, Interim Chief Executive Officer (CEO) Phillip Dennis, MD, PhD, Chief Medical Officer (CMO)
Webcast link	Here
Meetings	One-on-one and small group meetings: September 9 – 10, 2024
Management Participants	Sean Fu, PhD, Interim CEO Joe Skelton, Chief Financial Officer (CFO) Phillip Dennis, MD, PhD, CMO Tyler Ehler, Senior Director, Investor Relations

The webcast will also be available under "Event Calendar" on I-Mab's IR website at <https://ir.i-mabbio.com/>

For more information, please contact your H.C. Wainwright representative.

About I-Mab

I-Mab (NASDAQ: IMAB) is a US-based, global, clinical-stage biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer. I-Mab has established operations in Rockville, Maryland. For more information, please visit <https://www.i-mabbio.com> and follow us on LinkedIn and X.

For more information, please contact:

Tyler Ehler
Senior Director, Investor Relations
IR@imabbio.com

 View original content to download multimedia: <https://www.prnewswire.com/news-releases/i-mab-to-participate-at-the-hc-wainwright-26th-annual-global-investment-conference-302230144.html>

SOURCE I-Mab Biopharma